



Description	Incremental costs for denosumab with comparator (£)				Incremental QALYs for denosumab with comparator				ICERs for denosumab with comparator [ $\Delta$ cost (£)/ $\Delta$ QALY]			
	Zoledronic acid	Sodium pamidronate	Ibandronic acid		Zoledronic acid	Disodium pamidronate	Ibandronic acid		Zoledronic acid	Disodium pamidronate	Ibandronic acid	
Starting age												
Starting age = 50 years	-485	-3468	-1905		0.007	0.013	0.005		Denosumab dominant	Denosumab dominant	Denosumab dominant	
Starting age = 65 years	-479	-3416	-1868		0.007	0.013	0.005		Denosumab dominant	Denosumab dominant	Denosumab dominant	
Intravenous dosing frequency												
Based on UK treatment patterns of Q3-4W dosing	-786	-3895	-2281		0.007	0.013	0.005		Denosumab dominant	Denosumab dominant	Denosumab dominant	
Ibandronic acid												
Ibandronic acid administered orally	-483	-3453	49		0.007	0.013	0.005		Denosumab dominant	Denosumab dominant	9354	
Denosumab setting												
Community (district nurse)	-696	-3666	-2108		0.007	0.013	0.005		Denosumab dominant	Denosumab dominant	Denosumab dominant	
Discontinuation												
Zero for all treatments	-851	-3514	-1041		0.013	0.027	0.016		Denosumab dominant	Denosumab dominant	Denosumab dominant	
0.025 per cycle for all treatments	-467	-2019	-556		0.007	0.015	0.009		Denosumab dominant	Denosumab dominant	Denosumab dominant	
Discounting												
0% for costs and benefits	-515	-3724	-2087		0.008	0.014	0.005		Denosumab dominant	Denosumab dominant	Denosumab dominant	
0% for costs and 6% benefits	-515	-3724	-2087		0.007	0.013	0.005		Denosumab dominant	Denosumab dominant	Denosumab dominant	

AE, adverse event.

a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. *Ann Oncol* 2005;16: 579-584.

**TABLE 131** Prostate cancer, pain and history of a prior SRE with PAS

Description	Incremental costs for denosumab with comparator (£)	Incremental QALYs for denosumab with comparator	ICERs for denosumab with comparator [ $\Delta$ cost (£)/ $\Delta$ QALY]
	Zoledronic acid	Zoledronic acid	Zoledronic acid
Base case	-281	0.006	Denosumab dominant
Time horizon			
Time = 2 years	-240	0.005	Denosumab dominant
Time = 5 years	-279	0.006	Denosumab dominant
21-day window			
Without 21-day window	-350	0.010	Denosumab dominant
Asymptomatic events			
Include costs for trial-defined asymptomatic events	-307	0.006	Denosumab dominant
SRE costs			
Based on NHS reference costs	-215	0.006	Denosumab dominant
SRE utilities			
SRE utilities based on TTO	-281	0.006	Denosumab dominant
SRE utilities based on Weinfurt <i>et al.</i> 2005 <sup>a</sup>	-281	0.002	Denosumab dominant
AE utilities			
Normal model	-281	0.006	Denosumab dominant
Starting age			
Starting age = 50 years	-288	0.006	Denosumab dominant
Starting age = 80 years	-269	0.006	Denosumab dominant
Intravenous dosing frequency			
Based on UK treatment patterns of 3- to 4-weekly dosing	-469	0.006	Denosumab dominant
Denosumab setting			
Community (district nurse)	-412	0.006	Denosumab dominant
Discontinuation			
Zero for all treatments	-561	0.011	Denosumab dominant
0.025 per cycle for all treatments	-334	0.007	Denosumab dominant
Discounting			
0% for costs and benefits	-292	0.006	Denosumab dominant
0% for costs and 6% benefits	-292	0.006	Denosumab dominant

AE, adverse event.

a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, *et al.* The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer *Ann Oncol* 2005;**16**: 579–584.

**TABLE 132** Prostate cancer, no pain or pain and no history of a prior SRE with PAS

Description	Incremental costs for denosumab with comparator (£)	Incremental QALYs for denosumab with comparator	ICERs for denosumab with comparator [ $\Delta$ cost (£)/ $\Delta$ QALY]
	BSC	BSC	BSC
Base case	2790	0.039	71,320
Time horizon			
Time = 2 years	2562	0.030	84,079
Time = 5 years	2788	0.038	72,496
21-day window			
Without 21-day window	2584	0.051	51,153
Asymptomatic events			
Include costs for trial-defined asymptomatic events	2693	0.039	68,826
SRE costs			
Based on NHS reference costs	3044	0.039	77,796
SRE utilities			
Based on TTO	2790	0.023	120,262
Based on Weinfurt <i>et al.</i> 2005 <sup>a</sup>	2790	0.008	355,201
AE utilities			
Normal model	2790	0.039	71,415
Starting age			
Starting age = 50 years	2838	0.040	70,233
Starting age = 80 years	2702	0.037	73,343
Denosumab setting			
Community (district nurse)	2660	0.039	67,988
Discontinuation			
Zero for all treatments	5296	0.069	76,777
0.025 per cycle for all treatments	3408	0.047	72,572
Discounting			
0% for costs and benefits	2874	0.041	69,835
0% for costs and 6% benefits	2874	0.038	75,997

AE, adverse event.

a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, *et al.* The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer *Ann Oncol* 2005;**16**: 579–584.

**TABLE 133** Other solid tumours, pain and history of a prior SRE with PAS

Description	Incremental costs for denosumab with comparator (£)		Incremental QALYs for denosumab with comparator		ICERs for denosumab with comparator [ $\Delta$ cost (£)/ $\Delta$ QALY]	
	Zoledronic acid	Disodium pamidronate	Zoledronic acid	Disodium pamidronate	Zoledronic acid	Disodium pamidronate
Base case	-43	-2918	0.004	0.006	Denosumab dominant	Denosumab dominant
Time horizon						
Time = 2 years	-63	-2002	0.003	0.006	Denosumab dominant	Denosumab dominant
Time = 5 years	-44	-2726	0.004	0.006	Denosumab dominant	Denosumab dominant
21-day window						
Without 21-day window	-78	-2961	0.005	0.007	Denosumab dominant	Denosumab dominant
Asymptomatic events						
Include costs for trial-defined asymptomatic events	-56	-2934	0.004	0.006	Denosumab dominant	Denosumab dominant
SRE costs						
Based on NHS reference costs	-8	-2874	0.004	0.006	Denosumab dominant	Denosumab dominant
SRE utilities						
Based on TTO	-43	-2918	0.004	0.006	Denosumab dominant	Denosumab dominant
Based on Weinfurt <i>et al.</i> 2005 <sup>a</sup>	-43	-2918	0.002	0.003	Denosumab dominant	Denosumab dominant
AE utilities						
Normal model	-43	-2918	0.004	0.006	Denosumab dominant	Denosumab dominant
Starting age						
Starting age = 50 years	-43	-2935	0.004	0.006	Denosumab dominant	Denosumab dominant
Starting age = 70 years	-44	-2863	0.004	0.006	Denosumab dominant	Denosumab dominant
Intravenous dosing frequency						
Based on UK treatment patterns of 3- to 4-weekly dosing	-157	-3176	0.004	0.006	Denosumab dominant	Denosumab dominant
Denosumab setting						
Community (district nurse)	-130	-3004	0.004	0.006	Denosumab dominant	Denosumab dominant
Disodium pamidronate efficacy						

Description	Incremental costs for denosumab with comparator (£)		Incremental QALYs for denosumab with comparator		ICERs for denosumab with comparator [ $\Delta$ cost (£)/ $\Delta$ QALY]	
	Zoledronic acid	Disodium pamidronate	Zoledronic acid	Disodium pamidronate	Zoledronic acid	Disodium pamidronate
No efficacy (placebo treatment effect)	-43	-3181	0.004	0.011	Denosumab dominant	Denosumab dominant
Discontinuation						
Zero for all treatments	-469	-2274	0.008	0.018	Denosumab dominant	Denosumab dominant
0.025 per cycle for all treatments	-282	-1385	0.005	0.011	Denosumab dominant	Denosumab dominant
Discounting						
0% for costs and benefits	-40	-3112	0.004	0.006	Denosumab dominant	Denosumab dominant
0% for costs and 6% benefits	-40	-3112	0.004	0.006	Denosumab dominant	Denosumab dominant

AE, adverse event.

a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, *et al.* The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer *Ann Oncol* 2005;**16**: 579–584.

**TABLE 134** Other solid tumours, no pain or pain and no history of a prior SRE with PAS

Description	Incremental costs for denosumab with comparator (£)	Incremental QALYs for denosumab with comparator	ICERs for denosumab with comparator [ $\Delta$ cost (£)/ $\Delta$ QALY]
	BSC	BSC	BSC
Base case			
Time horizon	1730	0.021	83,763
Time = 2 years	1683	0.018	93,698
Time = 5 years	1735	0.020	85,522
21-day window			
Without 21-day window	1642	0.024	68,020
Asymptomatic events			
Include costs for trial-defined asymptomatic events	1683	0.021	81,497
SRE costs			
Based on NHS reference costs	1859	0.021	90,036
SRE utilities			
Based on TTO	1730	0.013	128,757
Based on Weinfurt <i>et al.</i> 2005 <sup>a</sup>	1730	0.005	319,401
AE utilities			
Normal model	1730	0.021	83,439
Starting age			
Starting age = 50 years	1732	0.021	83,606
Starting age = 70 years	1721	0.020	84,263
Denosumab setting			
Community (district nurse)	1643	0.021	79,565
Discontinuation			
Zero for all treatments	4109	0.042	97,505
0.025 per cycle for all treatments	2538	0.029	87,963
Discounting			
0% for costs and benefits	1765	0.021	82,207
0% for costs and 6% benefits	1765	0.020	87,728

AE, adverse event.

a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, *et al.* The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer *Ann Oncol* 2005;**16**: 579–584.